Noninvasive Markers of Portal Hypertension Detect Decompensation in Overweight or Obese Patients With Compensated Advanced Chronic Liver Disease

被引:18
|
作者
Mendoza, Yuly [1 ]
Cocciolillo, Sila [2 ]
Chen, Tianyan [1 ]
Margini, Cristina [2 ]
Sebastiani, Giada [1 ]
Berzigotti, Annalisa [2 ]
Murgia, Giuseppe [1 ]
机构
[1] Univ Bern, Bern Univ Hosp, Inselspital, Univ Clin Visceral Surg & Med,Dept Biomed Res, Bern, Switzerland
[2] McGill Univ, Royal Victoria Hosp, Div Gastroenterol & Hepatol, Hlth Ctr, Montreal, PQ, Canada
关键词
Cirrhosis; Ultrasound; NASH; Fibrosis; CONTROLLED ATTENUATION PARAMETER; STIFFNESS MEASUREMENT; RISK; COMPLICATIONS; PREDICTION; FIBROSIS;
D O I
10.1016/j.cgh.2020.04.018
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
BACKGROUND & AIMS: Some patients with compensated advanced chronic liver disease (cACLD) require use of an extralarge probe for liver stiffness measurement (LSM), owing to overweight or obesity. However, the ability of noninvasive markers of portal hypertension and the controlled attenuation parameter (CAP) to determine which of these patients are at risk for decompensation has not been fully assessed. METHODS: We collected data from 272 patients with cACLD (LSM double dagger 10 kPa by XL probe; 57% with nonalcoholic steatohepatitis; mean body mass index, 33.8 6.5 kg/m2; median Child-Pugh score, 5; median LSM, 16.8 kPa; mean CAP, 318 66 dB/m) evaluated at 2 academic centers from 2015 through 2018. We collected clinical data on decompensation (ascites, portal hypertension bleeding, jaundice, hepatic encephalopathy) and severe bacterial infections; patients were followed up for a median of 17 months (interquartile range, 11-24 mo). We evaluated associations between these events and LSM, CAP, LSM*spleen size/platelet count (LSPS), and portal hypertension risk scores. RESULTS: Decompensation occurred in 12 patients and severe bacterial infections developed in 5 patients. LSM, LSPS, and the portal hypertension risk score identified patients with decompensation with area under the receiver operating characteristic curve values of 0.848 (95% CI, 0.720-0.976; P < .0001), 0.881 (95% CI, 0.798-0.954; P < .0001), and 0.890 (95% CI, 0.814-0.966; P < .0001), respectively. In multivariate Cox regression analysis, in patients with nonalcoholic steatohepatitis, LSM and CAP were associated independently with decompensation and severe bacterial infection; CAP >= 220 dB/m was associated with a reduced risk of decompensation (hazard ratio, 0.043, 95% CI, 0.004-0.476; P =.01). CONCLUSIONS: LSM, LSPS, and the portal hypertension risk score identify obese or overweight patients with cACLD who are at increased risk of decompensation and severe bacterial infection.
引用
收藏
页码:3017 / +
页数:15
相关论文
共 50 条
  • [21] FIB-4 Improves LSM-Based Prediction of Complications in Overweight or Obese Patients With Compensated Advanced Chronic Liver Disease
    Mendoza, Yuly P.
    Shengir, Mohamed
    Bosch, Jaime
    Sebastiani, Giada
    Berzigotti, Annalisa
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2022, 20 (10) : 2396 - +
  • [22] Noninvasive Assessment of Nonalcoholic Fatty Liver Disease in Obese or Overweight Patients
    Francque, Sven M. A.
    Verrijken, An
    Mertens, Ilse
    Hubens, Guy
    Van Marck, Eric
    Pelckmans, Paul
    Michielsen, Peter
    Van Gaal, Luc
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2012, 10 (10) : 1162 - 1168
  • [23] The impact of first and further decompensation in patients with metabolic-dysfunction associated compensated advanced chronic liver disease
    Pennisi, G.
    Di Maria, G.
    Wong, V. Wai-Sun
    de Ledinghen, V.
    Sebastiani, G.
    Vigano, M.
    Fracanzani, A. L.
    Miele, L.
    Bugianesi, E.
    Ekstedt, M.
    D'Ambrosio, R.
    Schepis, F.
    Marra, F.
    Aghemo, A. M.
    Svegliati-Baroni, G.
    Persico, M.
    Valenti, L.
    Berzigotti, A.
    George, J.
    Ravaioli, F.
    Armandi, A.
    Calvaruso, V.
    Enea, M.
    Lin, H.
    Infantino, G.
    Masarone, M.
    Pugliese, N.
    Tulone, A.
    Di Marco, V.
    Camma, C.
    Petta, S.
    DIGESTIVE AND LIVER DISEASE, 2024, 56 : S316 - S317
  • [24] The impact of first and further decompensation in patients with metabolic-dysfunction associated compensated advanced chronic liver disease
    Pennisi, G.
    Di Maria, G.
    Wong, V. W. S.
    de Ledinghen, V.
    Sebastiani, G.
    Vigano, M.
    Fracanzani, A. L.
    Miele, L.
    Bugianesi, E.
    Ekstedt, M.
    D'Ambrosio, R.
    Ravaioli, F.
    Schepis, F.
    Marra, F.
    Aghemo, A. M.
    Svegliati-Baroni, G.
    Persico, M.
    Valenti, L.
    Berzigotti, A.
    George, J.
    Armandi, A.
    Nasr, P.
    Kechagias, S.
    Saltini, D.
    Mendoza, Y. P.
    Calvaruso, V.
    Enea, M.
    Lin, H.
    Infantino, G.
    Masarone, M.
    Pugliese, N.
    Tulone, A.
    Di Marco, V.
    Camma, C.
    Petta, S.
    DIGESTIVE AND LIVER DISEASE, 2025, 57
  • [25] Assessment of the Performance of Non-invasive Criteria for the Evaluation of Clinically Significant Portal Hypertension in Patients with Compensated Advanced Chronic Liver Disease
    Ankur Jindal
    Samagra Agarwal
    Sanchit Sharma
    Manoj Kumar
    Anoop Saraya
    Shiv Kumar Sarin
    Digestive Diseases and Sciences, 2023, 68 : 2149 - 2157
  • [26] Assessment of the Performance of Non-invasive Criteria for the Evaluation of Clinically Significant Portal Hypertension in Patients with Compensated Advanced Chronic Liver Disease
    Jindal, Ankur
    Agarwal, Samagra
    Sharma, Sanchit
    Kumar, Manoj
    Saraya, Anoop
    Sarin, Shiv Kumar
    DIGESTIVE DISEASES AND SCIENCES, 2023, 68 (05) : 2149 - 2157
  • [27] Prediction of the Esophageal Varices Needing Treatment with Noninvasive Tests in Patients with Compensated Advanced Chronic Liver Disease
    Lee, Hanah
    Kim, Seung Up
    Seo, Yeon Seok
    Lee, Young-Sun
    Kang, Seonghee
    Jung, Young Kul
    Kim, Moon Young
    Kim, Ji Hoon
    Kim, Sang Gyune
    Suk, Ki Tae
    Jung, Soung Won
    Jang, Jae Young
    Yim, Hyung Joon
    Um, Soonho
    HEPATOLOGY, 2018, 68 : 472A - 472A
  • [28] Performance of Controlled Attenuation Parameter in Patients with Advanced Chronic Liver Disease and Portal Hypertension
    Semmler, Georg
    Stift, Judith
    Scheiner, Bernhard
    Woeran, Katharina
    Schwabl, Philipp
    Paternostro, Rafael
    Bucsics, Theresa
    Staettermayer, Albert Friedrich
    Pinter, Matthias
    Ferlitsch, Arnulf
    Trauner, Michael
    Reiberger, Thomas
    Mandorfer, Mattias
    DIGESTIVE DISEASES AND SCIENCES, 2019, 64 (12) : 3642 - 3651
  • [29] Performance of Controlled Attenuation Parameter in Patients with Advanced Chronic Liver Disease and Portal Hypertension
    Georg Semmler
    Judith Stift
    Bernhard Scheiner
    Katharina Wöran
    Philipp Schwabl
    Rafael Paternostro
    Theresa Bucsics
    Albert Friedrich Stättermayer
    Matthias Pinter
    Arnulf Ferlitsch
    Michael Trauner
    Thomas Reiberger
    Mattias Mandorfer
    Digestive Diseases and Sciences, 2019, 64 : 3642 - 3651
  • [30] Noninvasive prediction of clinically significant portal hypertension and esophageal varices in patients with compensated liver cirrhosis
    Berzigotti, Annalisa
    Gilabert, Rosa
    Abraldes, Juan G.
    Nicolau, Carlos
    Bru, Concepcion
    Bosch, Jaime
    Garcia-Pagan, Juan C.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2008, 103 (05): : 1159 - 1167